Premium
Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma
Author(s) -
Fowler Jackson E.,
Bigler Steven A.,
Kolski John M.,
Yee David T.
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980315)82:6<1112::aid-cncr15>3.0.co;2-9
Subject(s) - medicine , prostate cancer , prospective cohort study , hormone therapy , antiandrogen , radiation therapy , carcinoma , hormonal therapy , prostate , androgen deprivation therapy , flutamide , surgery , oncology , cancer , breast cancer , androgen receptor
BACKGROUND Locally advanced prostate carcinoma is usually not curable with surgery or radiation therapy. Primary hormone therapy is an alternative therapeutic option, but contemporary prospective studies of the outcomes of such therapy are not available. METHODS The authors conducted a prospective, hospital‐based study of gonadal androgen ablation with deferred antiandrogen therapy in 103 men with prostate carcinoma clinically classified as T3‐4NXM0. The median potential follow‐up was 51 months (range, 36‐74 months), and the median period of observation was 43 months (range, 6‐74 months). RESULTS Each patient experienced regression of the primary tumor, and none experienced significant morbidity from the primary tumor during the study period. The projected 5‐year cause specific, metastasis free, PSA disease free (no PSA elevation > 1.0 ng/mL after the beginning of antiandrogen therapy), and all‐cause survival rates were 84%, 84%, 68%, and 58%, respectively. CONCLUSIONS Primary hormone therapy is a reasonable treatment option for locally advanced prostate carcinoma in elderly men or in men with significant comorbid disease who request therapeutic intervention. Cancer 1998;82:1112‐7. © 1998 American Cancer Society.